|1.||Kim, Nam Deuk: 9 articles (10/2008 - 03/2003)|
|2.||Suh, Hongsuk: 8 articles (10/2008 - 03/2003)|
|3.||Yoo, Young Hyun: 8 articles (04/2007 - 03/2003)|
|4.||Choi, Yung Hyun: 5 articles (10/2008 - 09/2003)|
|5.||Fiorucci, Stefano: 4 articles (12/2014 - 11/2004)|
|6.||Staels, Bart: 4 articles (03/2008 - 02/2003)|
|7.||Federico, A: 3 articles (01/2013 - 09/2001)|
|8.||Dotti, M T: 3 articles (01/2013 - 09/2001)|
|9.||Kosykh, Vladimir: 3 articles (11/2004 - 02/2003)|
|10.||Fruchart, Jean-Charles: 3 articles (11/2004 - 02/2003)|
03/01/1982 - "Of 125 patients with radiolucent gallstones in functioning gallbladders treated with chenodeoxycholic acid (CDCA) between 1971 and 1977, 47 showed complete gallstone dissolution--an overall efficacy of 38%. "
01/01/1980 - "Chenodeoxycholic acid (CDCA) is an effective treatment for dissolving gallstones but experimental studies have suggested that it might be hepatotoxic. "
03/01/2002 - "Most clinical trials on PBC therapy have used conservative dosages of UDCA similar to those of chenodeoxycholic acid (CDCA) used for dissolution of gallstones. "
09/01/1991 - "Samples were obtained from National Cooperative Gallstone Study patients (n = 17) with abnormal light microscopic liver biopsy results or major aminotransferase elevations and from a matched control group of patients (n = 14) who received similar chenodiol doses but had no evidence of liver injury. "
06/01/1990 - "One hundred and twelve patients with radiolucent gallstones entered the study; 54 received chenodeoxycholic acid (CDCA) and 58 ursodeoxycholic (UDCA) at dosage of 15 mg/kg/daily. "
|2.||Body Weight (Weight, Body)
12/01/2013 - "During the first 6 d after weaning, piglets were intragastrically infused once daily with either deionized water (control), chenodeoxycholic acid (CDC; 60 mg/kg body weight), or β-sitoesterol (BSE; 100 mg/kg body weight). "
08/01/1986 - "It was shown that feeding chenodeoxycholic acid (CDCA) for 24 days in dosages of 15, 30, and 60 mg/kg of body weight, all depressed PD equally but significantly (P less than 0.05) in three groups of dogs compared with a control group. "
06/01/1983 - "Chenodeoxycholic acid was given to 97 patients in a dosage of 15 mg/kg of body weight per day for a period of two years. "
11/01/1978 - "Chenodeoxycholic acid became a major bile acid averaging 10.4 +/- 1.6 mg/kg body weight/day. "
01/01/1985 - "Such patients may benefit from a trial of Chenodiol therapy at a dose of 15 mg/kg of body weight and experience both fewer symptoms and reduced need for medically indicated cholecystectomy. "
05/01/2013 - "Two neonatal cholestasis patients with mutations in the SRD5B1 (AKR1D1) gene: diagnosis and bile acid profiles during chenodeoxycholic acid treatment."
05/01/2005 - "Here, we describe the effect of 6-ethyl chenodeoxycholic acid (6-ECDCA or INT-747), a semisynthetic bile acid derivative and potent FXR ligand, in a model of cholestasis induced by 5-day administration of 17alpha-ethynylestradiol (E(2)17alpha) to rats. "
03/01/1995 - "Cholestatic concentrations of chenodeoxycholate conjugates directly inhibit the activity of microtubule motors, suggesting a possible mechanism for impairment of vesicular transport in cholestasis."
07/01/1993 - "Chenodeoxycholate is toxic to hepatocytes, and accumulation of chenodeoxycholate in the liver during cholestasis may potentiate hepatocellular injury. "
08/01/1992 - "Accordingly, we assessed the respective effects of cholestasis, chenodeoxycholic acid (CDCA), and UDCA, using mixed lymphocyte culture as a model of allogeneic immune response. "
|4.||Liver Diseases (Liver Disease)
05/01/2013 - "Primary bile acid treatment using chenodeoxycholic acid was effective for these patients treated in early infancy before the late stage of chronic cholestatic liver dysfunction."
03/01/1990 - "An ultrastructural study of patients with and without overt liver disease and the effect of chenodeoxycholic acid treatment."
03/01/1977 - "A perfusion technique has been used to study the effect of sodium chenodeoxycholate (5 mmol 1-1) on absorption of oxalate (2 mmol 1-1) from the surgically excluded colon in two patients with chronic liver disease. "
09/01/2014 - "Liver disease in infancy caused by oxysterol 7 α-hydroxylase deficiency: successful treatment with chenodeoxycholic acid."
05/01/2002 - "Ursodeoxycholate (the beta- epimer of chenodeoxycholate) is approved for the treatment of chronic cholestatic liver disease. "
01/01/1983 - "The aim of this study was to investigate whether the cathartic effect of chenodeoxycholic acid (CDCA) could be helpful in the management of chronic constipation. "
01/01/1983 - "Treatment of constipation with chenodeoxycholic acid."
11/01/2010 - "Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis."
12/01/1983 - "There was a significant improvement of constipation in the combined chenodeoxycholic acid groups when they were compared with the combined ursodeoxycholic acid groups. "
01/01/1994 - "Today, chenodeoxycholate has other medicinal uses and is used for the management of cerebrotendinous xanthomatosis, hypertriglyceremia, congenital liver diseases, rheumatoid arthritis, and constipation. "
|1.||Ursodeoxycholic Acid (Urso)
|4.||Bile Acids and Salts (Bile Acids)
|9.||Glycine (Aminoacetic Acid)
|1.||Lithotripsy (Extracorporeal Shockwave Lithotripsy)